PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
07 Mai 2024 - 3:19PM
PRISM MarketView announces the release of an insightful interview
with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as
the company works to disrupt the mature diagnostics marketplace
with a nimble, capital-light approach to growth.
Oncocyte (Nasdaq: OCX) has developed and is
preparing to commercialize precision tests in the transplant and
oncology markets. The Company’s transplant diagnostic tests,
VitaGraft™ and GraftAssure™, measure the health of a transplanted
organ via a simple blood test, and its oncology tests, DetermaIO™
and DetermaCNI™, measure individual patients’ suitability for and
response to immunotherapy. Mr. Riggs states in the interview, “We
want to ensure that clinicians and researchers will return to
Oncocyte’s products again and again, so our diagnostic products
have been designed with economics and ease of use in mind. Our
tests offer a streamlined workflow process that is uncomplicated,
inexpensive and fast, with results typically generated within four
to eight hours.”
In conversation with PRISM MarketView, Mr. Riggs
discusses Oncocyte’s partnering strategy, which the company
believes is a high-margin, low-complexity, scalable business model
that it expects to lead to substantially higher returns. “Building
out commercial teams can be incredibly expensive, and it doesn’t
always return shareholder value. Our strategy involves entering
partnerships with leading providers that have established
commercial channels, as we work to commercialize our distributable
kitted product,” states Mr. Riggs.
The full interview can be found at:
https://prismmarketview.com/oncocyte-disrupting-the-precision-diagnostics-marketplace-with-innovative-approach-to-growth/
About Oncocyte
Oncocyte is a precision diagnostics company. The
Company’s tests are designed to help provide clarity and confidence
to physicians and their patients. VitaGraft™ is a clinical
blood-based solid organ transplantation monitoring test,
GraftAssure™ is a research use only blood-based solid organ
transplantation monitoring test, DetermaIO™ is a gene expression
test that assesses the tumor microenvironment to predict response
to immunotherapies, and the pipeline test DetermaCNI™ is a
blood-based monitoring tool for monitoring therapeutic efficacy in
cancer patients. For more information, visit
https://oncocyte.com/
VitaGraft™, GraftAssure™, DetermaIO™, and
DetermaCNI™ are trademarks of Oncocyte Corporation.
About PRISM
MarketView:Established in 2020, PRISM MarketView is
dedicated to the monitoring and analysis of small cap stocks in
burgeoning sectors. We deliver up-to-the-minute financial market
news, provide comprehensive investor tools and foster a dynamic
investor community. Central to our offerings are proprietary
indexes that observe emerging sectors, including biotech, clean
energy, next-generation tech, medical devices and beyond. Visit us
at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment
advice.
Disclaimer
This communication was produced by PRISM
MarketView, an affiliate of PCG Advisory Inc., (together "PCG").
PCG is not a registered or licensed broker-dealer nor investment
adviser. No information contained in this communication constitutes
an offer to sell, a solicitation of an offer to buy, or a
recommendation of any security. PCG may be compensated by
respective clients for publicizing information relating to its
clients’ securities. See www.pcgadvisory.com/disclosures.
Contact:PRISM
MarketViewinfo@prismmarketview.com 646-863-6341
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/25cb802a-db18-4985-92ba-19bda2deaa04
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025